Equities analysts predict that Johnson & Johnson (NYSE:JNJ) will announce earnings of $1.98 per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Johnson & Johnson’s earnings, with the highest EPS estimate coming in at $2.10 and the lowest estimate coming in at $1.86. Johnson & Johnson reported earnings of $2.12 per share in the same quarter last year, which indicates a negative year-over-year growth rate of 6.6%. The business is scheduled to issue its next quarterly earnings results before the market opens on Tuesday, October 13th.
According to Zacks, analysts expect that Johnson & Johnson will report full year earnings of $7.85 per share for the current year, with EPS estimates ranging from $7.75 to $7.95. For the next year, analysts expect that the firm will report earnings of $8.94 per share, with EPS estimates ranging from $8.48 to $9.45. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Johnson & Johnson.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Thursday, July 16th. The company reported $1.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.50 by $0.17. Johnson & Johnson had a net margin of 22.69% and a return on equity of 35.21%. The business had revenue of $18.34 billion for the quarter, compared to the consensus estimate of $17.73 billion. During the same period in the prior year, the business posted $2.58 earnings per share. Johnson & Johnson’s revenue for the quarter was down 10.8% compared to the same quarter last year.
JNJ has been the topic of a number of research reports. Raymond James upped their price target on shares of Johnson & Johnson from $157.00 to $158.00 and gave the stock an “outperform” rating in a research note on Friday, July 17th. Independent Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and increased their target price for the stock from $161.00 to $164.00 in a research report on Monday, July 20th. ValuEngine raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Monday, August 3rd. Credit Suisse Group reissued a “buy” rating on shares of Johnson & Johnson in a research report on Friday, September 4th. Finally, SVB Leerink reissued an “outperform” rating on shares of Johnson & Johnson in a research report on Wednesday, July 15th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and eleven have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $163.00.
Shares of NYSE JNJ traded down $1.08 during mid-day trading on Monday, reaching $146.24. The company had a trading volume of 5,485,602 shares, compared to its average volume of 8,360,347. Johnson & Johnson has a twelve month low of $109.16 and a twelve month high of $157.00. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.99 and a current ratio of 1.25. The stock has a market capitalization of $385.02 billion, a PE ratio of 21.38, a price-to-earnings-growth ratio of 3.29 and a beta of 0.68. The stock’s 50 day moving average is $149.19 and its 200-day moving average is $144.96.
The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th were given a $1.01 dividend. This represents a $4.04 annualized dividend and a dividend yield of 2.76%. The ex-dividend date of this dividend was Monday, August 24th. Johnson & Johnson’s dividend payout ratio is currently 46.54%.
In related news, EVP Ashley Mcevoy sold 29,000 shares of the stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $147.47, for a total value of $4,276,630.00. Following the completion of the sale, the executive vice president now owns 21,682 shares in the company, valued at $3,197,444.54. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Kathryn E. Wengel sold 16,115 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the completion of the sale, the executive vice president now owns 66,658 shares of the company’s stock, valued at approximately $10,233,336.16. The disclosure for this sale can be found here. Company insiders own 0.27% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. increased its holdings in shares of Johnson & Johnson by 0.6% during the second quarter. BlackRock Inc. now owns 193,714,044 shares of the company’s stock worth $27,242,005,000 after buying an additional 1,168,129 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Johnson & Johnson by 1.5% in the first quarter. Geode Capital Management LLC now owns 38,965,156 shares of the company’s stock valued at $5,100,421,000 after purchasing an additional 572,077 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Johnson & Johnson by 10.8% in the first quarter. Wellington Management Group LLP now owns 30,556,662 shares of the company’s stock valued at $4,006,895,000 after purchasing an additional 2,968,879 shares in the last quarter. Massachusetts Financial Services Co. MA increased its holdings in shares of Johnson & Johnson by 7.7% in the first quarter. Massachusetts Financial Services Co. MA now owns 29,526,058 shares of the company’s stock valued at $3,871,753,000 after purchasing an additional 2,118,870 shares in the last quarter. Finally, Capital World Investors increased its holdings in shares of Johnson & Johnson by 182.9% in the first quarter. Capital World Investors now owns 21,195,989 shares of the company’s stock valued at $2,779,435,000 after purchasing an additional 13,703,905 shares in the last quarter. Institutional investors and hedge funds own 67.44% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: Price to Earnings Ratio (PE) Basics
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.